Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

482
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
482

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Recrudescence of a FLT3 wild-type CMML clone after allogeneic stem cell transplant for FLT3-ITD acute myeloid leukemia.

The oncologist·2026
Same author

Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.

Transplantation and cellular therapy·2026
Same author

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Blood immunology & cellular therapy·2026
Same author

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Donor Selection in the Post-Transplant Cyclophosphamide Era: Do the Little Things Matter?

JCO oncology practice·2026

Related Experiment Video

Updated: Aug 30, 2025

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.7K

Maintenance therapy for AML after allogeneic HCT.

Rahul K Nayak1, Yi-Bin Chen2

  • 1Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.

Frontiers in Oncology
|August 26, 2022
PubMed
Summary
This summary is machine-generated.

Maintenance therapy after allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) is crucial for preventing relapse. Ongoing research explores targeted agents, hypomethylating agents, and cellular therapies to improve outcomes.

Keywords:
AMLAML – acute myeloid leukaemiamaintenancerelapsetransplant

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

233

Related Experiment Videos

Last Updated: Aug 30, 2025

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.7K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

233

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Immunology

Background:

  • Allogeneic hematopoietic cell transplant (HCT) is a key treatment for acute myeloid leukemia (AML) in first complete remission.
  • Disease relapse post-HCT is a major challenge, often leading to poor prognosis.
  • There is a growing need for effective maintenance strategies to prevent AML recurrence after HCT.

Purpose of the Study:

  • To review the current landscape of maintenance therapy for AML following allo-HCT.
  • To explore emerging strategies and future directions in post-HCT AML maintenance.

Main Methods:

  • This review synthesizes current research and clinical trial data.
  • It examines various therapeutic modalities being investigated for AML maintenance post-HCT.

Main Results:

  • No therapies are currently approved for AML maintenance after allo-HCT.
  • Several promising approaches are under investigation, including targeted agents (FLT3-ITD, IDH inhibitors), hypomethylating agents, immunomodulatory drugs, and cellular therapies.

Conclusions:

  • Maintenance therapy holds significant potential for improving durable remission rates in high-risk AML patients post-allo-HCT.
  • Further research and clinical trials are essential to establish the optimal maintenance strategies and agents.